サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1747880

百日咳ワクチンの世界市場

Pertussis Vaccines

出版日
ページ情報
英文 285 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.08円
百日咳ワクチンの世界市場
出版日: 2025年06月13日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 285 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

百日咳ワクチンの世界市場は2030年までに83億米ドルに達する見込み

2024年に64億米ドルと推定される百日咳ワクチンの世界市場は、2024～2030年の分析期間においてCAGR 4.5%で成長し、2030年には83億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるDTaPワクチンは、CAGR 5.2%を記録し、分析期間終了時には57億米ドルに達すると予測されます。Tdapワクチン分野の成長率は、分析期間中CAGR 3.0%と推定されます。

米国市場は17億米ドル、中国はCAGR 8.3％で成長すると予測

米国の百日咳ワクチン市場は、2024年に17億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに17億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは8.3%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.8%と3.5%と予測されています。欧州では、ドイツがCAGR 2.6%で成長すると予測されています。

世界の百日咳ワクチン市場- 主要動向と促進要因まとめ

世界の予防接種戦略において百日咳ワクチン接種が急務となっているのはなぜか？

百日咳として一般的に知られている百日咳は、数十年にわたる予防接種プログラムにもかかわらず、依然として公衆衛生上の重大な脅威となっています。百日咳菌によって引き起こされるこの病気は、乳幼児や免疫不全者に深刻なリスクをもたらし、しばしば入院や致命的な呼吸器合併症を引き起こします。高所得国でも低所得国でも百日咳が再燃していることから、ワクチン接種率、ブースタープログラム、妊産婦への予防接種戦略に再び注目が集まっています。

百日咳の疫学が進化し、青少年や成人における発症率が増加していることから、ヘルスケア機関は予防接種スケジュールの改訂を促しています。現在では、思春期ブースター（Tdap）、介護者のコクーニング戦略、新生児に受動免疫を付与するための妊娠中の予防接種などが推奨されています。このような政策の転換は、有効性、反応原性、一般大衆の受容性などのプロファイルがそれぞれ異なるホールセル（wP）とアセルラー（aP）の両方の需要を支えています。

免疫力の低下とアウトブレイク管理に対する技術革新と再製剤化の取り組みは？

百日咳対策における大きな課題は、全細胞型ワクチンよりも安全ではあるもの、防御期間が短い非細胞型ワクチンに関連する免疫力の低下です。このため、ワクチン接種率が高い集団においても集団感染が発生しています。研究者や製造業者は、改良されたアジュバント、免疫原性の拡大、より広範な株数をカバーする次世代型ワクチンの開発に積極的に取り組んでいます。

開発中の新しい製剤には、弱毒化経鼻生ワクチン、遺伝的に無毒化された百日咳毒素、粘膜免疫の強化を目的としたナノ粒子ベースのアジュバントなどがあります。これらの技術革新は、特に学齢期の子どもやヘルスケア従事者など、感染の可能性が高い集団における集団免疫を強化することを目的としています。さらに、混合ワクチン（DTaP、Tdap-IPV-HepB-Hibなど）の進歩により、予防接種のロジスティクスが合理化され、小児および成人の集団におけるコンプライアンスが向上しています。

なぜ世界ヘルスへの取り組み、サプライチェーンの強化、政策枠組みが市場拡大に不可欠なのか？

Gavi、WHO、UNICEFなどの機関が主導する世界な予防接種の取り組みは、中低所得国における百日咳ワクチンアクセスの拡大において極めて重要な役割を担っています。これらの機関は調達、流通、コールドチェーン管理を支援する一方、ワクチン接種へのためらいを減らすための教育キャンペーンにも資金を提供しています。官民パートナーシップは、技術移転やライセンス契約を通じて、ワクチンの低価格化と現地生産をさらに促進しています。

百日咳サーベイランスを国の疾病監視システムに組み込むための政策枠組みも発展しています。統合された予防接種スケジュール、デジタル追跡ツール、キャッチアップキャンペーンは、免疫格差に対処するために実施されています。各国は母子保健プログラムの中で百日咳対策を優先するようになっており、ワクチンの需要と資金調達の両方を後押ししています。こうした市場開拓は市場の予測可能性を高め、バイオ医薬品企業による長期的な投資を促しています。

世界の百日咳ワクチン市場の継続的成長の原動力は？

百日咳ワクチン市場の成長は、疾病罹患率の上昇、妊産婦への予防接種プログラムの拡大、ワクチン開発における技術革新など、いくつかの要因によってもたらされます。主な成長要因は、乳幼児期を越えて、思春期、成人、高齢者を対象としたブースター・ベースの生涯予防接種戦略へのシフトです。

さらに、百日咳合併症に対する意識の高まり、診断サーベイランスの改善、混合ワクチンプラットフォームとの統合の進展が、市場の勢いをさらに強めています。世界の予防接種目標を達成し、予防可能な死亡を減少させるために各国が取り組みを拡大する中、百日咳ワクチンは国内および国際的な公衆衛生の課題の中心であり続けています。

百日咳の亜種の出現、予防接種インフラへのヘルスケア投資の増加、より安全で効果的なワクチン製剤への強い需要により、百日咳ワクチン市場は、公衆衛生および民間臨床の両分野において世界的に持続的な成長を遂げる位置にあります。

セグメント

タイプ（DTaPワクチン, Tdapワクチン）;エンドユーザー（予防接種センター,病院,クリニック,その他のエンドユーザー）

調査対象企業の例（注目の48社）

  • Astellas Pharma Inc.
  • Bharat Biotech International Limited
  • Biological E. Limited
  • BioNet-Asia Co., Ltd.
  • Cadila Healthcare Ltd.（Zydus Cadila）
  • Chiron Behring Vaccines Pvt. Ltd.
  • CSL Limited（Seqirus）
  • GlaxoSmithKline plc
  • Green Cross Corporation
  • Haffkine Bio-Pharmaceutical Corporation Ltd.
  • ILiAD Biotechnologies, LLC
  • Indian Immunologicals Ltd.
  • Merck & Co., Inc.
  • Panacea Biotec Ltd.
  • Pfizer Inc.
  • Sanofi Pasteur
  • Serum Institute of India Pvt. Ltd.
  • Shanta Biotechnics Pvt. Ltd.
  • Sinovac Biotech Ltd.
  • Wuhan Institute of Biological Products Co., Ltd.

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・業界団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP35508

Global Pertussis Vaccines Market to Reach US$8.3 Billion by 2030

The global market for Pertussis Vaccines estimated at US$6.4 Billion in the year 2024, is expected to reach US$8.3 Billion by 2030, growing at a CAGR of 4.5% over the analysis period 2024-2030. DTaP Vaccine, one of the segments analyzed in the report, is expected to record a 5.2% CAGR and reach US$5.7 Billion by the end of the analysis period. Growth in the Tdap Vaccine segment is estimated at 3.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.7 Billion While China is Forecast to Grow at 8.3% CAGR

The Pertussis Vaccines market in the U.S. is estimated at US$1.7 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.7 Billion by the year 2030 trailing a CAGR of 8.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.8% and 3.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.6% CAGR.

Global Pertussis Vaccines Market - Key Trends & Drivers Summarized

Why Is Pertussis Vaccination Regaining Urgency in Global Immunization Strategies?

Pertussis, commonly known as whooping cough, remains a significant public health threat despite decades of immunization programs. Caused by Bordetella pertussis, the disease poses severe risks to infants and immunocompromised individuals, often leading to hospitalization or fatal respiratory complications. The resurgence of pertussis in both high- and low-income countries is driving renewed focus on vaccine coverage, booster programs, and maternal immunization strategies.

The evolving epidemiology of pertussis-marked by increased incidence among adolescents and adults-has prompted healthcare agencies to revise immunization schedules. Recommendations now include adolescent boosters (Tdap), cocooning strategies for caregivers, and immunization during pregnancy to confer passive immunity to neonates. These policy shifts are supporting demand for both whole-cell (wP) and acellular (aP) pertussis vaccines, each with differing profiles of efficacy, reactogenicity, and public acceptance.

How Are Innovation and Reformulation Efforts Addressing Waning Immunity and Outbreak Management?

A major challenge in pertussis control is the waning immunity associated with acellular vaccines, which, although safer than whole-cell counterparts, provide shorter duration of protection. This has led to outbreaks even in highly vaccinated populations. Researchers and manufacturers are actively working on next-generation pertussis vaccines with improved adjuvants, extended immunogenicity, and broader strain coverage.

Novel formulations under development include live attenuated nasal vaccines, genetically detoxified pertussis toxins, and nanoparticle-based adjuvants aimed at enhancing mucosal immunity. These innovations are intended to strengthen herd immunity, especially in populations with high transmission potential such as school-aged children and healthcare workers. Additionally, advancements in combination vaccines (e.g., DTaP, Tdap-IPV-HepB-Hib) are streamlining immunization logistics and improving compliance in pediatric and adult populations.

Why Are Global Health Initiatives, Supply Chain Enhancements, and Policy Frameworks Vital to Market Expansion?

Global vaccination efforts led by organizations such as Gavi, WHO, and UNICEF continue to play a pivotal role in expanding pertussis vaccine access in low- and middle-income countries. These agencies support procurement, distribution, and cold-chain management while also funding education campaigns to reduce vaccine hesitancy. Public-private partnerships are further aiding vaccine affordability and localized production through technology transfers and licensing agreements.

Policy frameworks are also evolving to incorporate pertussis surveillance into national disease monitoring systems. Integrated immunization schedules, digital tracking tools, and catch-up campaigns are being implemented to address immunity gaps. Countries are increasingly prioritizing pertussis control within maternal and child health programs, boosting both demand and funding for vaccines. These systemic developments are improving market predictability and encouraging long-term investment by biopharmaceutical companies.

What’s Driving the Continued Growth of the Pertussis Vaccines Market Globally?

The growth in the pertussis vaccines market is driven by several factors including rising disease incidence, expansion of maternal immunization programs, and technological innovations in vaccine development. A key growth driver is the shift toward booster-based lifelong immunization strategies that extend coverage beyond infancy and target adolescents, adults, and seniors.

Moreover, the rising awareness of pertussis complications, improvements in diagnostic surveillance, and increased integration with combination vaccine platforms are further strengthening market momentum. As countries scale up efforts to meet global immunization targets and mitigate preventable deaths, pertussis vaccines remain central to national and international public health agendas.

With the ongoing emergence of pertussis variants, increasing healthcare investments in immunization infrastructure, and strong demand for safer, more effective vaccine formulations, the pertussis vaccines market is positioned for sustained global growth in both public health and private clinical sectors.

SCOPE OF STUDY:

The report analyzes the Pertussis Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (DTaP Vaccine, Tdap Vaccine); End-Use (Vaccination Centers, Hospitals, Clinics, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

  • Astellas Pharma Inc.
  • Bharat Biotech International Limited
  • Biological E. Limited
  • BioNet-Asia Co., Ltd.
  • Cadila Healthcare Ltd. (Zydus Cadila)
  • Chiron Behring Vaccines Pvt. Ltd.
  • CSL Limited (Seqirus)
  • GlaxoSmithKline plc
  • Green Cross Corporation
  • Haffkine Bio-Pharmaceutical Corporation Ltd.
  • ILiAD Biotechnologies, LLC
  • Indian Immunologicals Ltd.
  • Merck & Co., Inc.
  • Panacea Biotec Ltd.
  • Pfizer Inc.
  • Sanofi Pasteur
  • Serum Institute of India Pvt. Ltd.
  • Shanta Biotechnics Pvt. Ltd.
  • Sinovac Biotech Ltd.
  • Wuhan Institute of Biological Products Co., Ltd.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Pertussis Vaccines - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Whooping Cough Outbreaks Propels Global Demand for Pertussis Vaccination Programs
    • Expansion of Childhood Immunization Mandates Throws the Spotlight on Combination DTaP and Tdap Vaccines
    • OEM Innovation in Acellular and Subunit Vaccine Technologies Enhances Safety and Reduced Side Effects
    • Growth in Booster Dose Recommendations for Adolescents and Adults Strengthens Multi-Dose Market Opportunity
    • OEM Development of Thermostable Formulations Supports Vaccine Reach in Low-Infrastructure Regions
    • Surging Focus on Maternal Immunization Strategies Fuels Market for Pregnancy-Specific Pertussis Vaccines
    • OEM Participation in National Immunization Programs and GAVI Initiatives Enhances Global Procurement Volumes
    • Rising Antigenic Drift and Pathogen Evolution Spurs Development of Updated and Broader Spectrum Formulations
    • OEM Collaboration With Research Institutions Accelerates Understanding of Waning Immunity and Long-Term Protection
    • Growth in Combination Vaccine Markets Supports Integrated DTaP-HepB-IPV Platforms
    • OEM Investment in Intranasal and Needle-Free Delivery Platforms Improves Pediatric Vaccine Compliance
    • Rising Global Birth Rates and Population Growth Sustain Routine Infant Immunization Demand
    • OEM Emphasis on Adjuvant Development Enhances Immune Response in High-Risk Populations
    • Expansion of Cold Chain Logistics and Last-Mile Delivery Systems Boosts Reach in LMICs
    • OEM Engagement in Serosurveillance and Disease Burden Studies Informs Regional Vaccination Strategies
    • Regulatory Fast-Track and WHO Prequalification Initiatives Accelerate New Product Approvals
    • Growth in Adolescent and Occupational Health Programs Enhances Adult Tdap Uptake
    • OEM Differentiation Through Reduced Dosing Schedules and Combined Coverage Enhances Cost Effectiveness
    • Increasing Government Stockpiling and Pandemic Resilience Planning Supports Supply Security
    • OEM Entry Into Hexavalent and Decavalent Vaccine Platforms Drives Future Combination Strategies
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Pertussis Vaccines Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Pertussis Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Pertussis Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Pertussis Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for DTaP Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for DTaP Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for DTaP Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Tdap Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Tdap Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Tdap Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Vaccination Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Vaccination Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Vaccination Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Pertussis Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Pertussis Vaccines by Type - DTaP Vaccine and Tdap Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Pertussis Vaccines by Type - DTaP Vaccine and Tdap Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: USA 15-Year Perspective for Pertussis Vaccines by Type - Percentage Breakdown of Value Sales for DTaP Vaccine and Tdap Vaccine for the Years 2015, 2025 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Pertussis Vaccines by End-Use - Vaccination Centers, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Pertussis Vaccines by End-Use - Vaccination Centers, Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: USA 15-Year Perspective for Pertussis Vaccines by End-Use - Percentage Breakdown of Value Sales for Vaccination Centers, Hospitals, Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Pertussis Vaccines by Type - DTaP Vaccine and Tdap Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Pertussis Vaccines by Type - DTaP Vaccine and Tdap Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: Canada 15-Year Perspective for Pertussis Vaccines by Type - Percentage Breakdown of Value Sales for DTaP Vaccine and Tdap Vaccine for the Years 2015, 2025 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Pertussis Vaccines by End-Use - Vaccination Centers, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Pertussis Vaccines by End-Use - Vaccination Centers, Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: Canada 15-Year Perspective for Pertussis Vaccines by End-Use - Percentage Breakdown of Value Sales for Vaccination Centers, Hospitals, Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • JAPAN
    • Pertussis Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Pertussis Vaccines by Type - DTaP Vaccine and Tdap Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Pertussis Vaccines by Type - DTaP Vaccine and Tdap Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Japan 15-Year Perspective for Pertussis Vaccines by Type - Percentage Breakdown of Value Sales for DTaP Vaccine and Tdap Vaccine for the Years 2015, 2025 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Pertussis Vaccines by End-Use - Vaccination Centers, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Pertussis Vaccines by End-Use - Vaccination Centers, Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Japan 15-Year Perspective for Pertussis Vaccines by End-Use - Percentage Breakdown of Value Sales for Vaccination Centers, Hospitals, Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • CHINA
    • Pertussis Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 41: China Recent Past, Current & Future Analysis for Pertussis Vaccines by Type - DTaP Vaccine and Tdap Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Pertussis Vaccines by Type - DTaP Vaccine and Tdap Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: China 15-Year Perspective for Pertussis Vaccines by Type - Percentage Breakdown of Value Sales for DTaP Vaccine and Tdap Vaccine for the Years 2015, 2025 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Pertussis Vaccines by End-Use - Vaccination Centers, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Pertussis Vaccines by End-Use - Vaccination Centers, Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: China 15-Year Perspective for Pertussis Vaccines by End-Use - Percentage Breakdown of Value Sales for Vaccination Centers, Hospitals, Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • EUROPE
    • Pertussis Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Pertussis Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Pertussis Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Europe 15-Year Perspective for Pertussis Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Pertussis Vaccines by Type - DTaP Vaccine and Tdap Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Pertussis Vaccines by Type - DTaP Vaccine and Tdap Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Europe 15-Year Perspective for Pertussis Vaccines by Type - Percentage Breakdown of Value Sales for DTaP Vaccine and Tdap Vaccine for the Years 2015, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Pertussis Vaccines by End-Use - Vaccination Centers, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Pertussis Vaccines by End-Use - Vaccination Centers, Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Europe 15-Year Perspective for Pertussis Vaccines by End-Use - Percentage Breakdown of Value Sales for Vaccination Centers, Hospitals, Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • FRANCE
    • Pertussis Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for Pertussis Vaccines by Type - DTaP Vaccine and Tdap Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Pertussis Vaccines by Type - DTaP Vaccine and Tdap Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: France 15-Year Perspective for Pertussis Vaccines by Type - Percentage Breakdown of Value Sales for DTaP Vaccine and Tdap Vaccine for the Years 2015, 2025 & 2030
    • TABLE 59: France Recent Past, Current & Future Analysis for Pertussis Vaccines by End-Use - Vaccination Centers, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Pertussis Vaccines by End-Use - Vaccination Centers, Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: France 15-Year Perspective for Pertussis Vaccines by End-Use - Percentage Breakdown of Value Sales for Vaccination Centers, Hospitals, Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • GERMANY
    • Pertussis Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Pertussis Vaccines by Type - DTaP Vaccine and Tdap Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Pertussis Vaccines by Type - DTaP Vaccine and Tdap Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Germany 15-Year Perspective for Pertussis Vaccines by Type - Percentage Breakdown of Value Sales for DTaP Vaccine and Tdap Vaccine for the Years 2015, 2025 & 2030
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Pertussis Vaccines by End-Use - Vaccination Centers, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Pertussis Vaccines by End-Use - Vaccination Centers, Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Germany 15-Year Perspective for Pertussis Vaccines by End-Use - Percentage Breakdown of Value Sales for Vaccination Centers, Hospitals, Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Pertussis Vaccines by Type - DTaP Vaccine and Tdap Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Pertussis Vaccines by Type - DTaP Vaccine and Tdap Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Italy 15-Year Perspective for Pertussis Vaccines by Type - Percentage Breakdown of Value Sales for DTaP Vaccine and Tdap Vaccine for the Years 2015, 2025 & 2030
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Pertussis Vaccines by End-Use - Vaccination Centers, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Pertussis Vaccines by End-Use - Vaccination Centers, Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Italy 15-Year Perspective for Pertussis Vaccines by End-Use - Percentage Breakdown of Value Sales for Vaccination Centers, Hospitals, Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Pertussis Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for Pertussis Vaccines by Type - DTaP Vaccine and Tdap Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Pertussis Vaccines by Type - DTaP Vaccine and Tdap Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: UK 15-Year Perspective for Pertussis Vaccines by Type - Percentage Breakdown of Value Sales for DTaP Vaccine and Tdap Vaccine for the Years 2015, 2025 & 2030
    • TABLE 77: UK Recent Past, Current & Future Analysis for Pertussis Vaccines by End-Use - Vaccination Centers, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Pertussis Vaccines by End-Use - Vaccination Centers, Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: UK 15-Year Perspective for Pertussis Vaccines by End-Use - Percentage Breakdown of Value Sales for Vaccination Centers, Hospitals, Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Pertussis Vaccines by Type - DTaP Vaccine and Tdap Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Pertussis Vaccines by Type - DTaP Vaccine and Tdap Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Spain 15-Year Perspective for Pertussis Vaccines by Type - Percentage Breakdown of Value Sales for DTaP Vaccine and Tdap Vaccine for the Years 2015, 2025 & 2030
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Pertussis Vaccines by End-Use - Vaccination Centers, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Pertussis Vaccines by End-Use - Vaccination Centers, Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Spain 15-Year Perspective for Pertussis Vaccines by End-Use - Percentage Breakdown of Value Sales for Vaccination Centers, Hospitals, Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Pertussis Vaccines by Type - DTaP Vaccine and Tdap Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Pertussis Vaccines by Type - DTaP Vaccine and Tdap Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Russia 15-Year Perspective for Pertussis Vaccines by Type - Percentage Breakdown of Value Sales for DTaP Vaccine and Tdap Vaccine for the Years 2015, 2025 & 2030
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Pertussis Vaccines by End-Use - Vaccination Centers, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Pertussis Vaccines by End-Use - Vaccination Centers, Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Russia 15-Year Perspective for Pertussis Vaccines by End-Use - Percentage Breakdown of Value Sales for Vaccination Centers, Hospitals, Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Pertussis Vaccines by Type - DTaP Vaccine and Tdap Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Pertussis Vaccines by Type - DTaP Vaccine and Tdap Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 15-Year Perspective for Pertussis Vaccines by Type - Percentage Breakdown of Value Sales for DTaP Vaccine and Tdap Vaccine for the Years 2015, 2025 & 2030
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Pertussis Vaccines by End-Use - Vaccination Centers, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Pertussis Vaccines by End-Use - Vaccination Centers, Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 15-Year Perspective for Pertussis Vaccines by End-Use - Percentage Breakdown of Value Sales for Vaccination Centers, Hospitals, Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Pertussis Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Pertussis Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Pertussis Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 15-Year Perspective for Pertussis Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Pertussis Vaccines by Type - DTaP Vaccine and Tdap Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Pertussis Vaccines by Type - DTaP Vaccine and Tdap Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 15-Year Perspective for Pertussis Vaccines by Type - Percentage Breakdown of Value Sales for DTaP Vaccine and Tdap Vaccine for the Years 2015, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Pertussis Vaccines by End-Use - Vaccination Centers, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Pertussis Vaccines by End-Use - Vaccination Centers, Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 15-Year Perspective for Pertussis Vaccines by End-Use - Percentage Breakdown of Value Sales for Vaccination Centers, Hospitals, Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Pertussis Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Pertussis Vaccines by Type - DTaP Vaccine and Tdap Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Pertussis Vaccines by Type - DTaP Vaccine and Tdap Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Australia 15-Year Perspective for Pertussis Vaccines by Type - Percentage Breakdown of Value Sales for DTaP Vaccine and Tdap Vaccine for the Years 2015, 2025 & 2030
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Pertussis Vaccines by End-Use - Vaccination Centers, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Pertussis Vaccines by End-Use - Vaccination Centers, Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Australia 15-Year Perspective for Pertussis Vaccines by End-Use - Percentage Breakdown of Value Sales for Vaccination Centers, Hospitals, Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • INDIA
    • Pertussis Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 113: India Recent Past, Current & Future Analysis for Pertussis Vaccines by Type - DTaP Vaccine and Tdap Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Pertussis Vaccines by Type - DTaP Vaccine and Tdap Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: India 15-Year Perspective for Pertussis Vaccines by Type - Percentage Breakdown of Value Sales for DTaP Vaccine and Tdap Vaccine for the Years 2015, 2025 & 2030
    • TABLE 116: India Recent Past, Current & Future Analysis for Pertussis Vaccines by End-Use - Vaccination Centers, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Pertussis Vaccines by End-Use - Vaccination Centers, Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: India 15-Year Perspective for Pertussis Vaccines by End-Use - Percentage Breakdown of Value Sales for Vaccination Centers, Hospitals, Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Pertussis Vaccines by Type - DTaP Vaccine and Tdap Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Pertussis Vaccines by Type - DTaP Vaccine and Tdap Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: South Korea 15-Year Perspective for Pertussis Vaccines by Type - Percentage Breakdown of Value Sales for DTaP Vaccine and Tdap Vaccine for the Years 2015, 2025 & 2030
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Pertussis Vaccines by End-Use - Vaccination Centers, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Pertussis Vaccines by End-Use - Vaccination Centers, Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: South Korea 15-Year Perspective for Pertussis Vaccines by End-Use - Percentage Breakdown of Value Sales for Vaccination Centers, Hospitals, Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pertussis Vaccines by Type - DTaP Vaccine and Tdap Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Pertussis Vaccines by Type - DTaP Vaccine and Tdap Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 15-Year Perspective for Pertussis Vaccines by Type - Percentage Breakdown of Value Sales for DTaP Vaccine and Tdap Vaccine for the Years 2015, 2025 & 2030
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pertussis Vaccines by End-Use - Vaccination Centers, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Pertussis Vaccines by End-Use - Vaccination Centers, Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 15-Year Perspective for Pertussis Vaccines by End-Use - Percentage Breakdown of Value Sales for Vaccination Centers, Hospitals, Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Pertussis Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Pertussis Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Pertussis Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Latin America 15-Year Perspective for Pertussis Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Pertussis Vaccines by Type - DTaP Vaccine and Tdap Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Pertussis Vaccines by Type - DTaP Vaccine and Tdap Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Latin America 15-Year Perspective for Pertussis Vaccines by Type - Percentage Breakdown of Value Sales for DTaP Vaccine and Tdap Vaccine for the Years 2015, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Pertussis Vaccines by End-Use - Vaccination Centers, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Pertussis Vaccines by End-Use - Vaccination Centers, Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Latin America 15-Year Perspective for Pertussis Vaccines by End-Use - Percentage Breakdown of Value Sales for Vaccination Centers, Hospitals, Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Pertussis Vaccines by Type - DTaP Vaccine and Tdap Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Pertussis Vaccines by Type - DTaP Vaccine and Tdap Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Argentina 15-Year Perspective for Pertussis Vaccines by Type - Percentage Breakdown of Value Sales for DTaP Vaccine and Tdap Vaccine for the Years 2015, 2025 & 2030
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Pertussis Vaccines by End-Use - Vaccination Centers, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Pertussis Vaccines by End-Use - Vaccination Centers, Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Argentina 15-Year Perspective for Pertussis Vaccines by End-Use - Percentage Breakdown of Value Sales for Vaccination Centers, Hospitals, Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Pertussis Vaccines by Type - DTaP Vaccine and Tdap Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Pertussis Vaccines by Type - DTaP Vaccine and Tdap Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Brazil 15-Year Perspective for Pertussis Vaccines by Type - Percentage Breakdown of Value Sales for DTaP Vaccine and Tdap Vaccine for the Years 2015, 2025 & 2030
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Pertussis Vaccines by End-Use - Vaccination Centers, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Pertussis Vaccines by End-Use - Vaccination Centers, Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Brazil 15-Year Perspective for Pertussis Vaccines by End-Use - Percentage Breakdown of Value Sales for Vaccination Centers, Hospitals, Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Pertussis Vaccines by Type - DTaP Vaccine and Tdap Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Pertussis Vaccines by Type - DTaP Vaccine and Tdap Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Mexico 15-Year Perspective for Pertussis Vaccines by Type - Percentage Breakdown of Value Sales for DTaP Vaccine and Tdap Vaccine for the Years 2015, 2025 & 2030
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Pertussis Vaccines by End-Use - Vaccination Centers, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Pertussis Vaccines by End-Use - Vaccination Centers, Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Mexico 15-Year Perspective for Pertussis Vaccines by End-Use - Percentage Breakdown of Value Sales for Vaccination Centers, Hospitals, Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Pertussis Vaccines by Type - DTaP Vaccine and Tdap Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Pertussis Vaccines by Type - DTaP Vaccine and Tdap Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 15-Year Perspective for Pertussis Vaccines by Type - Percentage Breakdown of Value Sales for DTaP Vaccine and Tdap Vaccine for the Years 2015, 2025 & 2030
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Pertussis Vaccines by End-Use - Vaccination Centers, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Pertussis Vaccines by End-Use - Vaccination Centers, Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 15-Year Perspective for Pertussis Vaccines by End-Use - Percentage Breakdown of Value Sales for Vaccination Centers, Hospitals, Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Pertussis Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Pertussis Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Pertussis Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Middle East 15-Year Perspective for Pertussis Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Pertussis Vaccines by Type - DTaP Vaccine and Tdap Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Pertussis Vaccines by Type - DTaP Vaccine and Tdap Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Middle East 15-Year Perspective for Pertussis Vaccines by Type - Percentage Breakdown of Value Sales for DTaP Vaccine and Tdap Vaccine for the Years 2015, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Pertussis Vaccines by End-Use - Vaccination Centers, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Pertussis Vaccines by End-Use - Vaccination Centers, Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Middle East 15-Year Perspective for Pertussis Vaccines by End-Use - Percentage Breakdown of Value Sales for Vaccination Centers, Hospitals, Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Pertussis Vaccines by Type - DTaP Vaccine and Tdap Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Pertussis Vaccines by Type - DTaP Vaccine and Tdap Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Iran 15-Year Perspective for Pertussis Vaccines by Type - Percentage Breakdown of Value Sales for DTaP Vaccine and Tdap Vaccine for the Years 2015, 2025 & 2030
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Pertussis Vaccines by End-Use - Vaccination Centers, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Pertussis Vaccines by End-Use - Vaccination Centers, Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Iran 15-Year Perspective for Pertussis Vaccines by End-Use - Percentage Breakdown of Value Sales for Vaccination Centers, Hospitals, Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Pertussis Vaccines by Type - DTaP Vaccine and Tdap Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Pertussis Vaccines by Type - DTaP Vaccine and Tdap Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Israel 15-Year Perspective for Pertussis Vaccines by Type - Percentage Breakdown of Value Sales for DTaP Vaccine and Tdap Vaccine for the Years 2015, 2025 & 2030
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Pertussis Vaccines by End-Use - Vaccination Centers, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Pertussis Vaccines by End-Use - Vaccination Centers, Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Israel 15-Year Perspective for Pertussis Vaccines by End-Use - Percentage Breakdown of Value Sales for Vaccination Centers, Hospitals, Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Pertussis Vaccines by Type - DTaP Vaccine and Tdap Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Pertussis Vaccines by Type - DTaP Vaccine and Tdap Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 15-Year Perspective for Pertussis Vaccines by Type - Percentage Breakdown of Value Sales for DTaP Vaccine and Tdap Vaccine for the Years 2015, 2025 & 2030
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Pertussis Vaccines by End-Use - Vaccination Centers, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Pertussis Vaccines by End-Use - Vaccination Centers, Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 15-Year Perspective for Pertussis Vaccines by End-Use - Percentage Breakdown of Value Sales for Vaccination Centers, Hospitals, Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Pertussis Vaccines by Type - DTaP Vaccine and Tdap Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Pertussis Vaccines by Type - DTaP Vaccine and Tdap Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: UAE 15-Year Perspective for Pertussis Vaccines by Type - Percentage Breakdown of Value Sales for DTaP Vaccine and Tdap Vaccine for the Years 2015, 2025 & 2030
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Pertussis Vaccines by End-Use - Vaccination Centers, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Pertussis Vaccines by End-Use - Vaccination Centers, Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: UAE 15-Year Perspective for Pertussis Vaccines by End-Use - Percentage Breakdown of Value Sales for Vaccination Centers, Hospitals, Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Pertussis Vaccines by Type - DTaP Vaccine and Tdap Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Pertussis Vaccines by Type - DTaP Vaccine and Tdap Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 15-Year Perspective for Pertussis Vaccines by Type - Percentage Breakdown of Value Sales for DTaP Vaccine and Tdap Vaccine for the Years 2015, 2025 & 2030
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Pertussis Vaccines by End-Use - Vaccination Centers, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Pertussis Vaccines by End-Use - Vaccination Centers, Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 15-Year Perspective for Pertussis Vaccines by End-Use - Percentage Breakdown of Value Sales for Vaccination Centers, Hospitals, Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • AFRICA
    • Pertussis Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Pertussis Vaccines by Type - DTaP Vaccine and Tdap Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Pertussis Vaccines by Type - DTaP Vaccine and Tdap Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Africa 15-Year Perspective for Pertussis Vaccines by Type - Percentage Breakdown of Value Sales for DTaP Vaccine and Tdap Vaccine for the Years 2015, 2025 & 2030
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Pertussis Vaccines by End-Use - Vaccination Centers, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Pertussis Vaccines by End-Use - Vaccination Centers, Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Africa 15-Year Perspective for Pertussis Vaccines by End-Use - Percentage Breakdown of Value Sales for Vaccination Centers, Hospitals, Clinics and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION